Drug Profile
Valsartan extended release - Ezra Innovations
Alternative Names: EZR 104; valsartan XRLatest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator Ezra Pharma
- Class Antihypertensives; Branched-chain amino acids; Cardiovascular therapies; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Heart failure; Hypertension
Most Recent Events
- 25 Mar 2019 No recent reports of development identified for preregistration for Heart failure in USA (PO)
- 25 Mar 2019 No recent reports of development identified for preregistration for Hypertension in USA (PO)
- 14 Feb 2017 Chemical structure information added